SLC22A9

Across TCGA pan-cancer cohorts, SLC22A9 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SLC22A9 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher SLC22A9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC22A9 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

BLCA, STAD, and UCEC are the cancer types where SLC22A9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.060	0.657	<.001	42	view →
STAD	DFS	Median	All	1.000	0.368	.008	28	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SLC22A9–BLCA (OS)

Open the BLCA breakdown →